This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Bet on 4 Low-Beta MedTech Stocks to Ride the Choppy Market
by Riya Anand
Stocks like Henry Schein (HSIC), BellRing Brands (BRBR), Harrow Health (HROW) and West Pharmaceuticals Services (WST) are solid low-beta picks with strong fundamentals.
3 Best MedTech Growth Stocks to Bet On in 2021 Amid Pandemic
by Trina Mukherjee
Grab these three top stocks, EYE, WST and HSIC, which continue to show promise amid the pandemic and can turn out to be wise investment choices for 2021.
Reasons to Add West Pharmaceutical (WST) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about West Pharmaceutical (WST) due to its solid proprietary products segment.
Align (ALGN) to Launch Limited-Edition Invisalign Aligner Case
by Zacks Equity Research
Align (ALGN) partners with a popular social media star to release a limited-edition case for Invisalign aligners.
Patterson Companies (PDCO) Q4 Earnings Miss, Revenues Beat
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal fourth-quarter 2021 results benefit from strong segmental performance.
What's in Store for Patterson Companies' (PDCO) Q4 Earnings?
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal fourth-quarter results are likely to reflect improvement at Dental segment.
BD's (BDX) Rapid COVID-19 Test for US Olympic Trial Swimmers
by Zacks Equity Research
BD (BDX) to provide rapid antigen testing for COVID-19 at the U.S. Olympic Team Trials and other competitive swimming events on behalf of USA Swimming.
Walgreens (WBA) Rolls Out Plan to Boost COVID-19 Vaccination
by Zacks Equity Research
Walgreens Boots' (WBA) U.S. pharmacy segment to extend pharmacy timings for COVID-19 vaccination in support of Biden administration's vaccination efforts.
Is West Pharmaceutical (WST) a Great Growth Stock?
by Zacks Equity Research
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider West Pharmaceutical (WST).
Align Technology (ALGN) Launches New Features in iTero Family
by Zacks Equity Research
Align Technology's (ALGN) iTero Workflow 2.0 software and iTero Element 5D Imaging system auto-upload functionality to drive innovation in digital orthodontics and restorative dentistry.
Zimmer Biomet (ZBH) Witnesses Post-Pandemic Business Revival
by Zacks Equity Research
Zimmer Biomet's (ZBH) spin-off decision of the non-core dental and spine business is expected to prove strategic.
Henry Schein (HSIC) Clinches HHS Deal for COVID-19 Supplies
by Zacks Equity Research
Henry Schein (HSIC) to extend effective inventory management and extensive logistical support for PPE and COVID related products within the spectrum of U.S. health care.
Medtronic (MDT) Diabetes Arm Secures Two Approvals in Europe
by Zacks Equity Research
These two latest innovations are likely to enable Medtronic (MDT) to offer the only pump that adjusts and corrects every five minutes with an infusion set that lasts twice as long.
3 Reasons Growth Investors Will Love West Pharmaceutical (WST)
by Zacks Equity Research
West Pharmaceutical (WST) is well positioned to outperform the market, as it exhibits above-average growth in financials.
3 Reasons Why Growth Investors Shouldn't Overlook West Pharmaceutical (WST)
by Zacks Equity Research
West Pharmaceutical (WST) possesses solid growth attributes, which could help it handily outperform the market.
Amedisys (AMED) to Buy VNA Hospice, Home Health, Expand in NE
by Zacks Equity Research
The acquisition is going to expand Amedisys' (AMED) presence in Omaha and Council Bluffs' healthcare communities.
Zimmer Biomet's (ZBH) Recovery to Continue Despite Pandemic
by Zacks Equity Research
Zimmer Biomet's (ZBH) spin-off decision of the non-core dental and spine business is expected to prove strategic.
Zacks.com featured highlights include: DAQO New Energy, Louisiana Pacific, Nucor Corp, West Pharmaceutical Services and PulteGroup
by Zacks Equity Research
Zacks.com featured highlights include: DAQO New Energy, Louisiana Pacific, Nucor Corp, West Pharmaceutical Services and PulteGroup
5 Stocks With Low Debt-to-Equity Ratio to Boost Your Portfolio
by Aparajita Dutta
For a prudent investor, a safe strategy of choosing stocks should include search for stocks that bear a low leverage. You may buy DQ, LPX, NUE, WST and PHM.
LabCorp (LH) Base Line Growth Solid, COVID-Related Sales Drop
by Zacks Equity Research
LabCorp's (LH) Walgreens-partnership expands to include new integrated digital experiences.
Henry Schein (HSIC) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Henry Schein (HSIC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
These 5 Growth Stocks Are Worth a Closer Look
by Sejuti Banerjea
This may be a good time to invest in growth stocks.
West Pharmaceutical (WST) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
West Pharmaceutical (WST) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Illumina (ILMN) Q1 Earnings Top Estimates, Margins Decline
by Zacks Equity Research
Illumina (ILMN) exhibits an impressive performance by its Instruments segment in the first quarter of 2021 despite pandemic-led business disruptions.
West Pharmaceutical Services (WST) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
West Pharmaceutical (WST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.